Latest Siga Technologies Inc (SIGA) Headlines
SIGA Technologies Reports Financial Results for the Fourth Quarter and Year Ended 2013
GlobeNewswire - Mon Mar 10, 3:01PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today reported its financial results for the quarter and year ended December 31, 2013.
SIGA to Host Quarterly Business Update Call on March 10, 2014
GlobeNewswire - Mon Mar 03, 4:20PM CST
SIGA Technologies, Inc. (Nasdaq:SIGA) announced today that management will host a conference call and simultaneous webcast to provide a quarterly business update at 4:30 P.M. ET on Monday, March 10, 2014.
Ebola and Marburg Infections - Pipeline Review, H2 2013 Report
M2 - Tue Feb 04, 2:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv7mx8/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola and Marburg Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola and Marburg Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Inovio Pharmaceuticals, Inc. Bavarian Nordic A/S Crucell N.V. NanoViricides, Inc. SIGA Technologies, Inc. Functional Genetics, Inc. Okairos AG AlphaVax, Inc. Immunovaccine, Inc. Mapp Biopharmaceutical, Inc. For more information visit http://www.researchandmarkets.com/research/bv...nd_marburg About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SIGA Technologies Reports Financial Results for the Third Quarter 2013
GlobeNewswire - Wed Nov 06, 3:30PM CST
SIGA Technologies, Inc. (Nasdaq:SIGA) today reported its financial results for the three and nine months ended September 30, 2013.
SIGA to Host Third Quarter Business Update Call on November 6, 2013
GlobeNewswire - Mon Nov 04, 3:05PM CST
SIGA Technologies, Inc. (Nasdaq:SIGA) announced today that management will host a conference call and simultaneous webcast to provide a quarterly business update at 5:00 P.M. ET on Wednesday, November 6, 2013.
Deal Or No Deal: 6 Stocks Under 5 Bucks With Buy Ratings
at The Street - Wed Oct 16, 3:41PM CDT
Global Smallpox Clinical Trials Review, H2, 2013
M2 - Tue Oct 15, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xg46m/smallpox_global) has announced the addition of the "Smallpox Global Clinical Trials Review, H2, 2013" report to their offering. Smallpox Global Clinical Trials Review, H2, 2013" provides data on the Smallpox clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Smallpox. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Smallpox. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Smallpox Therapeutics Clinical Trials - Bavarian Nordic A/S - Sanofi - SIGA Technologies, Inc. - Cangene Corporation - Chimerix, Inc. - Sanofi Pasteur, Inc. - VaxGen, Inc. (Inactive) - DynPort Vaccine Company LLC For more information visit http://www.researchandmarkets.com/research/3x...pox_global
Dengue - Pipeline Review, H2 2013
M2 - Thu Oct 10, 2:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6x783/dengue_pipeline) has announced the addition of the "Dengue - Pipeline Review, H2 2013" report to their offering. 'Dengue - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dengue, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dengue. Scope - A snapshot of the global therapeutic scenario for Dengue. - A review of the Dengue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dengue pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. GlaxoSmithKline plc GenVec, Inc. Merck & Co., Inc. Takeda Pharmaceutical Company Limited Biological E. Limited Biotron Limited AVI BioPharma Inc. Medivir AB NanoViricides, Inc. SIGA Technologies, Inc. Panacea Biotec Limited Functional Genetics, Inc. Advinus Therapeutics Pvt. Ltd. Protein Potential, LLC TechnoVax, Inc. MacroGenics, Inc. PTC Therapeutics, Inc. Chimerix, Inc. Wittycell S.A.S. Immunotope, Inc. ImmunoVaccine Technologies Inc. Ortho-McNeil Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/p6...e_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Encephalitis - Pipeline Review, H2 2013
M2 - Thu Sep 12, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l8dt7p/encephalitis) has announced the addition of the "Encephalitis - Pipeline Review, H2 2013" report to their offering. 'Encephalitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Encephalitis, complete with latest updates, and special features on late-stage and discontinued projects. Scope - A snapshot of the global therapeutic scenario for Encephalitis. - A review of the Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Encephalitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Sanofi-Aventis Takeda Pharmaceutical Company Limited CEL-SCI Corporation SIGA Technologies, Inc. Panacea Biotec Limited Functional Genetics, Inc. Palau Pharma S.A AlphaVax, Inc. EpiVax, Inc. Wittycell S.A.S. Vaxart, Inc. Hawaii Biotech, Inc. NasVax Ltd. Prosetta Corporation Vaxine Pty Ltd For more information visit http://www.researchandmarkets.com/research/l8...cephalitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SIGA Technologies Reports Financial Results for the Second Quarter 2013
GlobeNewswire - Mon Aug 05, 3:00PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) today reported its financial results for the three and six months ended June 30, 2013.
Stock to Watch: SIGA Technologies Up 11.1% (SIGA)
Comtex SmarTrend(R) - Fri Aug 02, 10:16AM CDT
SIGA Technologies (NASDAQ:SIGA) is one of today's best performing low-priced stocks, up 11.1% to $3.61 on 1.4x average daily volume. SIGA Technologies has traded 315,000 shares thus far today, vs. average volume of 233,000 shares per day. The stock has outperformed the Dow (11.1% to the Dow's -0.4%) and outperformed the S&P 500 (11.1% to the S&P's -0.3%) during today's trading.
SIGA Selects Lead Candidate for Dengue Antiviral Program
GlobeNewswire - Thu Aug 01, 4:00PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) today announced that it has selected a lead candidate for its dengue fever antiviral program.
SIGA to Host Second Quarter Business Update Call on August 5, 2013
GlobeNewswire - Tue Jul 30, 3:00PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) announced today that management will host a conference call and simultaneous webcast to provide a quarterly business update at 4:30 P.M. ET on Monday, August 5, 2013.
Siga qualifies for $79M smallpox drug payment
AP - Tue Jul 16, 10:26AM CDT
NEW YORK (AP) — Shares of Siga Technologies Inc. climbed Tuesday after the company said it qualified for about $79 million in payments after delivering more doses of its smallpox drug to the government.
Traders Get Bullish on Shares of SIGA Technologies, Shares Up 8.0% (SIGA)
Comtex SmarTrend(R) - Tue Jul 16, 10:17AM CDT
SIGA Technologies (NASDAQ:SIGA) is one of today's best performing low-priced stocks, up 8.0% to $3.51 on 1.2x average daily volume. SIGA Technologies has traded 294,000 shares thus far today, vs. average volume of 255,000 shares per day. The stock has outperformed the Dow (8.0% to the Dow's -0.2%) and outperformed the S&P 500 (8.0% to the S&P's -0.3%) during today's trading.
SIGA Meets Drug Delivery Condition Under BARDA Contract and Qualifies for First Payment for Delivering Arestvyr(TM)
GlobeNewswire - Tue Jul 16, 7:30AM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) today announced it has passed another significant commercial milestone with the third delivery of its proprietary smallpox antiviral drug, Arestvyr(TM), to the United States Government's Strategic National Stockpile (SNS). With a cumulative delivery of approximately 590,000 courses of Arestvyr to the SNS over the past five months, SIGA has met a key requirement of its contract with the Government's Biomedical Advanced Research and Development Authority (BARDA) and has qualified for a payment of approximately $79 million for the courses delivered to date.
SIGA, TESS, BVSN, SMTX, ZOLT Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Jul 02, 6:02AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of SIGA Technologies Inc (NASDAQ:SIGA), TESSCO TECHNOLOGIES INCORPORATED (NASDAQ:TESS), BroadVision Inc (NASDAQ:BVSN), SMTC Corp (NASDAQ:SMTX), Zoltek Companies Inc (NASDAQ:ZOLT) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Ebola and Marburg Infections - Pipeline Review, H1 2013
M2 - Mon Jun 17, 6:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h7wtzj/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H1 2013" report to their offering. "Ebola and Marburg Infections - Pipeline Review, H1 2013", provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages.
SIGA Completes Second Delivery of Arestvyr(TM) Under BARDA Contract
GlobeNewswire - Wed May 29, 7:30AM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) today announced the Government's acceptance of SIGA's second delivery of its proprietary smallpox antiviral drug, Arestvyr(TM), to the United States Government's Strategic National Stockpile (SNS) under SIGA's contract with the Biomedical Advanced Research and Development Authority (BARDA).
Delaware high court: SIGA liable in contract row
By The Associated Press - AP - Sun May 26, 5:17PM CDT
The Delaware Supreme Court has upheld a lower court's finding that SIGA Technologies Inc. is liable for breaching contractual obligations to negotiate in good faith with rival biodefense company PharmAthene.
SIGA Technologies Reports Financial Results for the Fourth Quarter and Year Ended 2013
GlobeNewswire - Mon Mar 10, 3:01PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today reported its financial results for the quarter and year ended December 31, 2013.
SIGA to Host Quarterly Business Update Call on March 10, 2014
GlobeNewswire - Mon Mar 03, 4:20PM CST
SIGA Technologies, Inc. (Nasdaq:SIGA) announced today that management will host a conference call and simultaneous webcast to provide a quarterly business update at 4:30 P.M. ET on Monday, March 10, 2014.
Ebola and Marburg Infections - Pipeline Review, H2 2013 Report
M2 - Tue Feb 04, 2:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv7mx8/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola and Marburg Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola and Marburg Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Inovio Pharmaceuticals, Inc. Bavarian Nordic A/S Crucell N.V. NanoViricides, Inc. SIGA Technologies, Inc. Functional Genetics, Inc. Okairos AG AlphaVax, Inc. Immunovaccine, Inc. Mapp Biopharmaceutical, Inc. For more information visit http://www.researchandmarkets.com/research/bv...nd_marburg About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SIGA Technologies Reports Financial Results for the Third Quarter 2013
GlobeNewswire - Wed Nov 06, 3:30PM CST
SIGA Technologies, Inc. (Nasdaq:SIGA) today reported its financial results for the three and nine months ended September 30, 2013.
SIGA to Host Third Quarter Business Update Call on November 6, 2013
GlobeNewswire - Mon Nov 04, 3:05PM CST
SIGA Technologies, Inc. (Nasdaq:SIGA) announced today that management will host a conference call and simultaneous webcast to provide a quarterly business update at 5:00 P.M. ET on Wednesday, November 6, 2013.
Deal Or No Deal: 6 Stocks Under 5 Bucks With Buy Ratings
at The Street - Wed Oct 16, 3:41PM CDT
Global Smallpox Clinical Trials Review, H2, 2013
M2 - Tue Oct 15, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xg46m/smallpox_global) has announced the addition of the "Smallpox Global Clinical Trials Review, H2, 2013" report to their offering. Smallpox Global Clinical Trials Review, H2, 2013" provides data on the Smallpox clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Smallpox. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Smallpox. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Smallpox Therapeutics Clinical Trials - Bavarian Nordic A/S - Sanofi - SIGA Technologies, Inc. - Cangene Corporation - Chimerix, Inc. - Sanofi Pasteur, Inc. - VaxGen, Inc. (Inactive) - DynPort Vaccine Company LLC For more information visit http://www.researchandmarkets.com/research/3x...pox_global
Dengue - Pipeline Review, H2 2013
M2 - Thu Oct 10, 2:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6x783/dengue_pipeline) has announced the addition of the "Dengue - Pipeline Review, H2 2013" report to their offering. 'Dengue - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dengue, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dengue. Scope - A snapshot of the global therapeutic scenario for Dengue. - A review of the Dengue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dengue pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. GlaxoSmithKline plc GenVec, Inc. Merck & Co., Inc. Takeda Pharmaceutical Company Limited Biological E. Limited Biotron Limited AVI BioPharma Inc. Medivir AB NanoViricides, Inc. SIGA Technologies, Inc. Panacea Biotec Limited Functional Genetics, Inc. Advinus Therapeutics Pvt. Ltd. Protein Potential, LLC TechnoVax, Inc. MacroGenics, Inc. PTC Therapeutics, Inc. Chimerix, Inc. Wittycell S.A.S. Immunotope, Inc. ImmunoVaccine Technologies Inc. Ortho-McNeil Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/p6...e_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Encephalitis - Pipeline Review, H2 2013
M2 - Thu Sep 12, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l8dt7p/encephalitis) has announced the addition of the "Encephalitis - Pipeline Review, H2 2013" report to their offering. 'Encephalitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Encephalitis, complete with latest updates, and special features on late-stage and discontinued projects. Scope - A snapshot of the global therapeutic scenario for Encephalitis. - A review of the Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Encephalitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Sanofi-Aventis Takeda Pharmaceutical Company Limited CEL-SCI Corporation SIGA Technologies, Inc. Panacea Biotec Limited Functional Genetics, Inc. Palau Pharma S.A AlphaVax, Inc. EpiVax, Inc. Wittycell S.A.S. Vaxart, Inc. Hawaii Biotech, Inc. NasVax Ltd. Prosetta Corporation Vaxine Pty Ltd For more information visit http://www.researchandmarkets.com/research/l8...cephalitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SIGA Technologies Reports Financial Results for the Second Quarter 2013
GlobeNewswire - Mon Aug 05, 3:00PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) today reported its financial results for the three and six months ended June 30, 2013.
Stock to Watch: SIGA Technologies Up 11.1% (SIGA)
Comtex SmarTrend(R) - Fri Aug 02, 10:16AM CDT
SIGA Technologies (NASDAQ:SIGA) is one of today's best performing low-priced stocks, up 11.1% to $3.61 on 1.4x average daily volume. SIGA Technologies has traded 315,000 shares thus far today, vs. average volume of 233,000 shares per day. The stock has outperformed the Dow (11.1% to the Dow's -0.4%) and outperformed the S&P 500 (11.1% to the S&P's -0.3%) during today's trading.
SIGA Selects Lead Candidate for Dengue Antiviral Program
GlobeNewswire - Thu Aug 01, 4:00PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) today announced that it has selected a lead candidate for its dengue fever antiviral program.
SIGA to Host Second Quarter Business Update Call on August 5, 2013
GlobeNewswire - Tue Jul 30, 3:00PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) announced today that management will host a conference call and simultaneous webcast to provide a quarterly business update at 4:30 P.M. ET on Monday, August 5, 2013.
Siga qualifies for $79M smallpox drug payment
AP - Tue Jul 16, 10:26AM CDT
NEW YORK (AP) — Shares of Siga Technologies Inc. climbed Tuesday after the company said it qualified for about $79 million in payments after delivering more doses of its smallpox drug to the government.
Traders Get Bullish on Shares of SIGA Technologies, Shares Up 8.0% (SIGA)
Comtex SmarTrend(R) - Tue Jul 16, 10:17AM CDT
SIGA Technologies (NASDAQ:SIGA) is one of today's best performing low-priced stocks, up 8.0% to $3.51 on 1.2x average daily volume. SIGA Technologies has traded 294,000 shares thus far today, vs. average volume of 255,000 shares per day. The stock has outperformed the Dow (8.0% to the Dow's -0.2%) and outperformed the S&P 500 (8.0% to the S&P's -0.3%) during today's trading.
SIGA Meets Drug Delivery Condition Under BARDA Contract and Qualifies for First Payment for Delivering Arestvyr(TM)
GlobeNewswire - Tue Jul 16, 7:30AM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) today announced it has passed another significant commercial milestone with the third delivery of its proprietary smallpox antiviral drug, Arestvyr(TM), to the United States Government's Strategic National Stockpile (SNS). With a cumulative delivery of approximately 590,000 courses of Arestvyr to the SNS over the past five months, SIGA has met a key requirement of its contract with the Government's Biomedical Advanced Research and Development Authority (BARDA) and has qualified for a payment of approximately $79 million for the courses delivered to date.
SIGA, TESS, BVSN, SMTX, ZOLT Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Jul 02, 6:02AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of SIGA Technologies Inc (NASDAQ:SIGA), TESSCO TECHNOLOGIES INCORPORATED (NASDAQ:TESS), BroadVision Inc (NASDAQ:BVSN), SMTC Corp (NASDAQ:SMTX), Zoltek Companies Inc (NASDAQ:ZOLT) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Ebola and Marburg Infections - Pipeline Review, H1 2013
M2 - Mon Jun 17, 6:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h7wtzj/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H1 2013" report to their offering. "Ebola and Marburg Infections - Pipeline Review, H1 2013", provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages.
SIGA Completes Second Delivery of Arestvyr(TM) Under BARDA Contract
GlobeNewswire - Wed May 29, 7:30AM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) today announced the Government's acceptance of SIGA's second delivery of its proprietary smallpox antiviral drug, Arestvyr(TM), to the United States Government's Strategic National Stockpile (SNS) under SIGA's contract with the Biomedical Advanced Research and Development Authority (BARDA).
Delaware high court: SIGA liable in contract row
By The Associated Press - AP - Sun May 26, 5:17PM CDT
The Delaware Supreme Court has upheld a lower court's finding that SIGA Technologies Inc. is liable for breaching contractual obligations to negotiate in good faith with rival biodefense company PharmAthene.
